Avanos Medical (NYSE:AVNS) Sets New 12-Month High – Here’s Why

Avanos Medical, Inc. (NYSE:AVNS) shares reached a new 52-week high during trading on Tuesday . The stock traded as high as $24.58 and last traded at $24.5450, with a volume of 12314663 shares trading hands. The stock had previously closed at $14.53.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Zacks Research upgraded Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Avanos Medical in a report on Monday, December 22nd. Finally, Wall Street Zen upgraded Avanos Medical from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce”.

Avanos Medical Stock Up 69.2%

The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.26 and a current ratio of 2.15. The firm has a market cap of $1.14 billion, a PE ratio of -15.56 and a beta of 1.05. The stock has a fifty day moving average price of $14.05 and a 200-day moving average price of $12.52.

Avanos Medical (NYSE:AVNS) last issued its earnings results on Tuesday, February 24th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.05. Avanos Medical had a positive return on equity of 5.47% and a negative net margin of 10.40%.The business had revenue of $180.90 million during the quarter, compared to analysts’ expectations of $174.70 million. During the same quarter in the previous year, the business earned $0.43 EPS. The company’s revenue for the quarter was up .7% on a year-over-year basis. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. Research analysts expect that Avanos Medical, Inc. will post 1.32 EPS for the current year.

Institutional Trading of Avanos Medical

A number of institutional investors have recently modified their holdings of the company. Federated Hermes Inc. grew its holdings in shares of Avanos Medical by 2.8% during the 4th quarter. Federated Hermes Inc. now owns 25,774 shares of the company’s stock worth $289,000 after purchasing an additional 691 shares during the period. Versant Capital Management Inc grew its holdings in shares of Avanos Medical by 49.7% during the 3rd quarter. Versant Capital Management Inc now owns 2,692 shares of the company’s stock worth $31,000 after purchasing an additional 894 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Avanos Medical by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock worth $386,000 after purchasing an additional 1,121 shares during the period. Azzad Asset Management Inc. ADV lifted its position in Avanos Medical by 3.0% during the 3rd quarter. Azzad Asset Management Inc. ADV now owns 43,230 shares of the company’s stock worth $500,000 after acquiring an additional 1,240 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in Avanos Medical by 132.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock worth $28,000 after acquiring an additional 1,423 shares in the last quarter. Hedge funds and other institutional investors own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.